Oct 10,2022

Attention Deficit and Digital Therapeutics

TALi CEO and Chief Medical Officer, Dr Mary-Beth Brinson, featured on the Parenting and Personalities Podcast with Kate Mason. Dr Brinson discusses how attention is critical to children in the development of cognitive skills – it’s the development of their ability to process sensory information which leads to better memory, problem solving, and general thinking. Attention training has been around for years, but this new and exciting method is now emerging.

View Analyst & Ambassador Comments
Go to original news
Oct 24,2022

Highmark steps up coverage of prescription digital therapies including EndeavorRx from Akili

Highmark plans to expand insurance coverage for some prescription digital therapeutics cleared by the Food and Drug Administration, marking a major step forward for app makers in the market. Highmark, a provider-payer organization, is not the first payer to cover some prescription digital therapeutics, also called PDTs. The policy names eight products, including Akili Interactive’s EndeavorRx; Pear Therapeutics’ cognitive behavioral therapy (CBT) apps for the treatment of opiate user disorder, substance use disorder and insomnia; a treatment for nightmares paired with the Apple Watch; apps targeting irritable bowel syndrome; and virtual reality-based treatments for chronic lower back pain and lazy eye.

COLLABORATION PARTNERSHIP

#insurance

#cbt

#pdt

View Analyst & Ambassador Comments
Go to original news
Nov 09,2022

Twill partners to add teletherapy for higher acuity care

Digital therapeutics company Twill, previously known as Happify Health, is partnering with e-Psychiatry to offer virtual access to psychiatrists, psychologists and therapists. Conn.-based e-Psychiatry's services will be offered as an element of Twill's Sequences, a platform made up of digital therapeutics, community groups and coaching aimed at mental health conditions and pregnancy.

COLLABORATION PARTNERSHIP

#product & service

#coaching

#virtual care

View Analyst & Ambassador Comments
Go to original news
Nov 16,2022

YourCoach.Health Announces Partnership with Feel Therapeutics to Deliver Live Health Coaching Through Feel's Digital Health Programs

YourCoach.Health, the industry's only operating system for behavior change powered by health coaches, today announced a partnership with Feel Therapeutics, a leading company developing digital biomarkers and therapeutics to bring objective measurement and data in mental health. YourCoach will leverage its verified cohort of cross-specialty coaches to power Feel's live health coaching offerings within Feel's digital health and therapeutics programs.

COLLABORATION PARTNERSHIP

#product & service

#coaching

View Analyst & Ambassador Comments
Go to original news
Nov 29,2022

First study to utilize digital therapeutics on rare lung disease begins national patient enrollment

A first-of-its-kind digital therapeutics research study may offer new hope for patients with a rare lung disease and are having difficulty with anxiety. Vicore Pharma recently launched the study across the U.S. The Vicore COMPANION Study will test Almee™, a digital cognitive behavioral therapy (CBT). The COMPANION study, a fully digitized, randomized, controlled parallel-group clinical investigation, will examine the impact of Almee™ on anxiety in patients with PF by looking at the change from baseline in anxiety symptom severity assessed by GAD-7. 

CLINICAL STUDY

#cbt

#pdt

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jul 07,2021

Putting digital therapeutics to work for mental health

National Institute of Mental Health data shows that more than 17.3 million U.S. adults have suffered from an episode of major depression in the past year, and one in three are afflicted by an anxiety disorder. Mental health conditions often go underdiagnosed and undertreated. People also are facing added pressures from COVID-19, which is causing isolation, fear of the virus and financial pressures. In a preview of his HIMSS21 session, the chief digital engagement officer of Froedtert & the Medical College of Wisconsin describes how a mental health app has helped the health system's patients.

View Analyst & Ambassador Comments
Go to original news
Jul 12,2021

Sober Grid Users to Gain Access to Clinically Proven Digital Therapeutics Through New Commercial Partnership with Orexo

Sober Grid, the largest social media network for those in addiction recovery, and Orexo, a Swedish pharmaceutical company, today announced that Sober Grid’s more than 300,000 users will gain access to Orexo’s clinically proven digital therapeutics for problematic alcohol use (vorvida®) and depression (deprexis®) through their new partnership. The Sober Grid community will be able to take advantage of vorvida® and deprexis®, digital therapies that help reduce problematic drinking patterns in adults and manage symptoms of depression, respectively, starting August 2021.

COLLABORATION PARTNERSHIP

#product & service

View Analyst & Ambassador Comments
Go to original news
Jul 20,2021

Without judgment: How digital therapeutics is destigmatizing mental health treatment

DTx helps reduce mental health stigma that is a barrier for underrepresented populations to receiving mental health care and if developed with intention and within a culturally-responsive framework, DTx won’t judge or discriminate.

#cbt

View Analyst & Ambassador Comments
Go to original news
Jul 23,2021

Happify rolls out digital therapeutic for anxiety, depression under temporary FDA guidance

Happify is making its app-based treatment available to patients thanks to a loosened FDA guidance last year that lets digital health companies targeting some behavioral health conditions release their product without clearance. The company is launching an investigational study to get data for a future FDA submission. The company’s new digital therapeutic, called Ensemble, uses app-based exercises to help people change negative thinking patterns and develop healthy habits. It’s not FDA cleared, and is only available by prescription or through an investigational study. Happify plans to use real-world data to submit its product for clearance in the next 18 to 24 months, head of digital therapeutics Chris Wasden wrote in an emailed statement.

PRODUCT

#mobile app

#cbt

View Analyst & Ambassador Comments
Go to original news
Jul 28,2021

CEO of digital therapeutics business Freespira talks about its approach to anxiety disorders

Freespira CEO Dean Sawyer said the company's FDA cleared digital therapeutic is the first that’s proven to significantly reduce or eliminate symptoms of panic attacks, panic disorder, and PTSD, in a single, 28-day treatment episode. Sawyer provides an overview of how Freespira is treating anxiety disorders with an FDA cleared digital therapeutic.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Subscribe to MENTAL HEALTH